パーキンソン症候群
WordNet
- a pattern of symptoms indicative of some disease
- a complex of concurrent things; "every word has a syndrome of meanings"
PrepTutorEJDIC
- (疾患の徴候となる一群の)症徴候,症候群 / (事件・社会的状態などのパターンを示す)徴候形態
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/03/10 23:12:24」(JST)
[Wiki en表示]
| Parkinsonism |
| Classification and external resources |
| ICD-10 |
G20-G21 |
| ICD-9 |
332 |
| DiseasesDB |
24212 |
| MedlinePlus |
000759 |
| MeSH |
D020734 |
Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural instability.[1][2] Parkinsonism shares symptoms found in Parkinson's Disease, from which it is named; but parkinsonism is a symptom complex, and differs from Parkinson disease which is a progressive neurodegenerative illness. The underlying causes of parkinsonism are numerous, and diagnosis can be complex.[3][4] The neurodegenerative condition Parkinson's disease (PD) is the most common cause of parkinsonism. However, a wide range of other etiologies may lead to a similar set of symptoms, including some toxins, a few metabolic diseases, and a handful of neurological conditions other than Parkinson's.[5]
About 7% of people with parkinsonism have developed their symptoms following treatment with particular medications. Side effect of medications, mainly neuroleptic antipsychotics especially the phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupenthixol and zuclopenthixol) and butyrophenones (such as haloperidol (Haldol)), piperazines (such as ziprasidone), and, rarely, antidepressants. The incidence of drug-induced parkinsonism increases with age. Drug induced parkinsonism tends to remain at its presenting level, i.e. does not progress like the parkinson disease.[6]
Contents
- 1 Etiology
- 1.1 Progressive supranuclear palsy (PSP)
- 1.2 Corticobasal ganglionic degeneration (CBGD)
- 1.3 Multiple system atrophy (MSA)
- 1.4 Dementia with Lewy bodies (DLB)
- 1.5 Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)
- 1.6 Parkinsonism-dementia complex of Guam (PDC)
- 1.7 Vascular parkinsonism
- 1.8 Toxin-induced parkinsonism
- 2 Differential diagnoses
- 3 References
- 4 External links
§Etiology
§Progressive supranuclear palsy (PSP)
§Corticobasal ganglionic degeneration (CBGD)
§Multiple system atrophy (MSA)
§Dementia with Lewy bodies (DLB)
§Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)
§Parkinsonism-dementia complex of Guam (PDC)
§Vascular parkinsonism
§Toxin-induced parkinsonism
§Differential diagnoses
Before Parkinson's disease is diagnosed the differential diagnoses include:
- AIDS can sometimes lead to the symptoms of secondary parkinsonism, due to commonly causing dopaminergic dysfunction. Indeed parkinsonism can be a presenting feature of HIV infection.[7]
- Corticobasal degeneration[1]
- Creutzfeldt-Jakob disease[8]
- Dementia pugilistica or "boxer's dementia" is a condition that occurs in boxers due to chronic brain trauma
- Diffuse Lewy body disease[1]
- Drug-induced parkinsonism ("pseudoparkinsonism") due to drugs such as antipsychotics, metoclopramide, MPTP[1][9]
- Encephalitis lethargica[1]
- Essential tremor, an illness which has some diagnostic overlap with Parkinson's disease.[10]
- Multiple system atrophy[11]
- Pantothenate kinase-associated neurodegeneration, also known as Neurodegeneration with brain iron accumulation (NBIA) or Hallervorden-Spatz syndrome[12][13]
- Parkinson plus syndrome
- Progressive supranuclear palsy[1]
- Toxicity due to substances such as carbon monoxide,[14] carbon disulfide,[14] manganese,[14] paraquat,[15] mercury,[16] hexane, rotenone, and toluene[17] (inhalant abuse: "huffing")[18]
- Vascular parkinsonism[19][20]
- Wilson's disease is a genetic disorder in which there is an abnormal accumulation of copper. The excess copper can lead to the formation of a copper-dopamine complex, which leads to the oxidation of dopamine to aminochrome.[21] The most common manifestations include bradykinesia, cogwheel rigidity[22] and a lack of balance.[23]
- Paraneoplastic syndrome: neurological symptoms caused by antibodies associated with cancers
- Genetic
- Rapid onset dystonia parkinsonism (DYT12)
- Parkin mutation
- X-linked dystonia parkinsonism (DYT3)
- Autosomal recessive juvenile parkinsonism (ARJP)
§References
- ^ a b c d e f Aminoff MJ, Greenberg DA, Simon RP (2005). Clinical Neurology (6th ed.). Lange: McGraw-Hill Medical. pp. 241–5. ISBN 0-07-142360-5.
- ^ Bradley J. Robottom; William J. Weiner; Lisa M. Shulman. "42". International Neurology: A Clinical Approach. Blackwell Publishing Ltd. pp. 152–158. ISBN 978-1-405-15738-4.
- ^ Rao G, Fisch L, Srinivasan S, et al. Does this patient have Parkinson disease? JAMA. 2003;289(3):347-353. PMID 12525236
- ^ Tuite PJ, Krawczewski K (2007). "Parkinsonism: a review-of-systems approach to diagnosis". Seminars in neurology 27 (2): 113–22. doi:10.1055/s-2007-971174. PMID 17390256.
- ^ Christine CW, Aminoff MJ (2004). "Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance". Am. J. Med. 117 (6): 412–9. doi:10.1016/j.amjmed.2004.03.032. PMID 15380498.
- ^ http://www.parkinsons.org.uk/PDF/FS38_druginducedparkinsonism.pdf
- ^ Tse W; Cersosimo MG; Gracies JM et al. (2004). "Movement disorders and AIDS: a review". Parkinsonism Relat. Disord. 10 (6): 323–34. doi:10.1016/j.parkreldis.2004.03.001. PMID 15261874.
- ^ Maltête D, Guyant-Maréchal L, Mihout B, Hannequin D (2006). "Movement disorders and Creutzfeldt-Jakob disease: a review". Parkinsonism Relat. Disord. 12 (2): 65–71. doi:10.1016/j.parkreldis.2005.10.004. PMID 16364674.
- ^ Watanabe Y, Himeda T, Araki T (2005). "Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease" (PDF). Med. Sci. Monit. 11 (1): RA17–23. PMID 15614202.
- ^ http://www.news-medical.net/news/20090902/LINGO1-variant-responsible-for-essential-tremors-and-Parkinsons-disease.aspx
- ^ Wenning GK, Geser F (2003). "Multiple system atrophy". Rev. Neurol. (Paris) 159 (5 Pt 2): 3S31–8. PMID 12773886.
- ^ Uc EY, Rodnitzky RL (2003). "Childhood dystonia". Seminars in pediatric neurology 10 (1): 52–61. doi:10.1016/S1071-9091(02)00010-4. PMID 12785748.
- ^ Online 'Mendelian Inheritance in Man' (OMIM) NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1 -234200
- ^ a b c DeLong MR, Juncos JL (2004). Parkinson's Disease and Other Movement Disorders. In: Harrison's Principles of Internal Medicine (16th ed.). McGraw-Hill Professional. p. 2414. ISBN 0-07-140235-7.
- ^ Dinis-Oliveira RJ; Remião F; Carmo H et al. (2006). "Paraquat exposure as an etiological factor of Parkinson's disease". Neurotoxicology 27 (6): 1110–22. doi:10.1016/j.neuro.2006.05.012. PMID 16815551.
- ^ Tremor/InvoluntaryMovements: Excerpt from Field Guide to Bedside Diagnosis
- ^ Weiss J. Chapter 151. Toluene and Xylene. In: Olson KR, ed. Poisoning & Drug Overdose. 6th ed. New York: McGraw-Hill; 2012. http://www.accessmedicine.com/content.aspx?aID=55982958. Accessed April 21, 2013.
- ^ http://onlinelibrary.wiley.com/doi/10.1002/ana.410350516/abstract
- ^ Thanvi B, Lo N, Robinson T (2005). "Vascular Parkinsonism--an important cause of parkinsonism in older people" (PDF). Age and ageing 34 (2): 114–9. doi:10.1093/ageing/afi025. PMID 15713855.
- ^ http://parkinsonsdiseasefoundation.blogspot.com/2012/08/vascular-parkinsonism.html
- ^ Członkowska A; Tarnacka B; Möller JC et al. (2007). "Unified Wilson's Disease Rating Scale — a proposal for the neurological scoring of Wilson's disease patients". Neurol. Neurochir. Pol. 41 (1): 1–12. PMID 17330175.
- ^ Ropper AH, Samuels MA. Chapter 4. Abnormalities of Movement and Posture Caused by Disease of the Basal Ganglia. In: Ropper AH, Samuels MA, eds. Adams and Victor's Principles of Neurology. 9th ed. New York: McGraw-Hill; 2009. http://www.accessmedicine.com/content.aspx?aID=3630437. Accessed April 21, 2013.
- ^ Lorincz MT (January 2010). "Neurologic Wilson's disease". Ann. N. Y. Acad. Sci. 1184: 173–87. doi:10.1111/j.1749-6632.2009.05109.x. PMID 20146697.
§External links
- GeneReviews/NIH/NCBI/UW entry on Perry syndrome
- GeneReviews/NCBI/NIH/UW entry on X-Linked Dystonia-Parkinsonism
|
Antiparkinson agents (N04)
|
|
| Dopaminergics |
|
DA precursors/prodrugs
|
- Etilevodopa
- Droxidopa
- Levodopa#
- Melevodopa
|
|
|
DA receptor agonists
|
- Aplindore
- Apomorphine
- Bromocriptine
- Cabergoline
- Ciladopa
- Dihydroergocryptine
- Lisuride
- Pardoprunox
- Pergolide
- Piribedil
- Pramipexole
- Ropinirole
- Rotigotine
|
|
|
MAO-B inhibitors
|
- Ladostigil
- Lazabemide
- Mofegiline
- Pargyline‡
- Rasagiline
- Selegiline
|
|
|
COMT inhibitors
|
- Entacapone
- Nitecapone
- Tolcapone
|
|
|
Aromatic L-amino acid decarboxylase inhibitors
|
- Benserazide
- Carbidopa#
- Methyldopa
|
|
|
| Anticholinergics |
- Benzatropine
- Biperiden#
- Bornaprine
- Chlorphenoxamine
- Cycrimine
- Dexetimide
- Dimenhydrinate
- Diphenhydramine
- Etanautine
- Etybenzatropine
- Mazaticol
- Metixene
- Orphenadrine
- Phenglutarimide
- Piroheptine
- Procyclidine
- Profenamine
- Trihexyphenidyl
- Tropatepine
|
|
| Others |
- Amantadine
- Budipine
- MDMA
- Memantine
- Methylxanthines
- Rimantadine
- UWA-101
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
Index of the central nervous system
|
|
| Description |
- Anatomy
- meninges
- cortex
- association fibers
- commissural fibers
- lateral ventricles
- basal ganglia
- diencephalon
- mesencephalon
- pons
- cerebellum
- medulla
- spinal cord
- Physiology
- Development
|
|
| Disease |
- Meningitis
- Demyelinating diseases
- Seizures and epilepsy
- Headache
- Stroke
- Sleep
- Congenital
- Injury
- Neoplasms and cancer
- Other
- Symptoms and signs
- head and neck
- eponymous
- lesions
|
|
| Treatment |
- Procedures
- Drugs
- general anesthetics
- analgesics
- addiction
- epilepsy
- cholinergics
- migraine
- Parkinson's
- vertigo
- other
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: A 24 months pilot observational open-label study.
- Moretti DV1, Binetti G2, Zanetti O2, Frisoni GB2.
- Neuropharmacology.Neuropharmacology.2014 Oct;85:284-9. doi: 10.1016/j.neuropharm.2014.05.028. Epub 2014 Jun 7.
- Rotigotine (RTG) is a non-ergot dopamine agonist developed as a new transdermal formulation, indicated for use in early and advanced Parkinson's disease (PD). The potential advantages of the RTG patch include immediacy of effect onset, constant drug delivery, better tolerability avoiding drug peaks
- PMID 24915072
- Tau protein, beta-amyloid1-42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
- Vranová HP1, Hényková E2, Kaiserová M3, Menšíková K3, Vaštík M3, Mareš J3, Hluštík P3, Zapletalová J4, Strnad M2, Stejskal D5, Kaňovský P3.
- Journal of the neurological sciences.J Neurol Sci.2014 Aug 15;343(1-2):120-4. doi: 10.1016/j.jns.2014.05.052. Epub 2014 Jun 2.
- BACKGROUND: Parkinson's disease (PD), PD with dementia (PDD) and Lewy body dementia (DLB) are synucleinopathies. PDD and DLB are sometimes considered a transition between PD and Alzheimer dementia (AD). Finding in vivo markers or their combination could help in the differential diagnosis of these ne
- PMID 24928081
- Creativity and neurological disease.
- Acosta LM.
- Current neurology and neuroscience reports.Curr Neurol Neurosci Rep.2014 Aug;14(8):464. doi: 10.1007/s11910-014-0464-6.
- Although humans have long valued creativity, the generation of such innovation is still incompletely understood. Looking at the healthy brain, researchers have localized certain parts for a basic understanding of these mechanisms. By researching the brain affected by neurological disease, scientists
- PMID 24938215
Japanese Journal
- パーキンソン関連疾患における経頭蓋超音波検査による中脳黒質の高輝度変化の検討
- 岩波 正興,宮本 智之,宮本 雅之,高田 悦雄,平田 幸一
- Dokkyo journal of medical sciences 38(1), 103-109, 2011-03-25
- … Vの割合は,PD 72.4%,MSA 10.0%,PSP 66.7%,健常者3.1%であった.定量評価では,PD 63.8%,MSA 20.0%,PSP 66.7%,健常者9.4%で病的な高輝度変化をみとめた.PD,PSP で病的な高輝度変化の割合が多かった.PSP をPSP-parkinsonism( PSPP)とRichardson's syndrome の2 群に分けた場合,前者では病的な高輝度変化を3 例中3 例 (100%), 後者では3 例中1 例( 33.3%) に認められ,PSP-P で割合が高かった.MSA では10 例中2 例( 20%) に病的な高輝度を認め,いずれもパーキンソン病型の多系 …
- NAID 110008449024
- 多系統萎縮症との鑑別を要した多腺性自己免疫症候群関連パーキンソン症候群の1例
- 小林 正武,南里 和紀,田中 伸幸,長谷川 明,田口 丈士,齊藤 和裕
- 臨床神経学 50(10), 704-709, 2010-10-01
- NAID 10027870244
Related Links
- syndrome Med any combination of signs and symptoms that are indicative of a particular disease or disorder syndrome [′sin‚drōm] (medicine) A group of signs and symptoms which together characterize a disease. Also known as ...
- par·kin·so·ni·an (pär′kĭn-sō′nē-ən) adj. Relating to Parkinsonism. parkinsonian. See Parkinson's disease. parkinsonian [pahr″kin-so´ne-an] pertaining to parkinsonism. parkinsonian syndrome any disorder manifesting the symptoms of parkinson's disease
Related Pictures
★リンクテーブル★
[★]
- 英
- parkinsonian syndrome
- 同
- Parkinson症候群
- 関
- パーキンソニズム parkinsonism
[show details]
分類
中枢神経変性疾患 - パーキンソンニズムを主徴とする疾患
[★]
- 英
- parkinsonian syndrome
- 関
- パーキンソニズム、パーキンソン症候群、若年性パーキンソニズム、常染色体劣性若年性パーキンソニズム、若年性パーキンソン病、Parkinsonian症候群、常染色体優性パーキソニズム、実験的パーキソニズム、常染色体劣性若年性パーキンソン病、パーキンソン症状、パーキンソン様症状、MPTP誘発実験的パーキンソニズム、常染色体劣性遺伝パーキンソニズム
[★]
常染色体劣性若年性パーキンソニズム、常染色体劣性遺伝性若年性パーキンソニズム
- 関
- autosomal dominant parkinsonism、autosomal recessive juvenile Parkinson disease、autosomal recessive parkinsonism、experimental parkinsonism、juvenile Parkinson disease、juvenile parkinsonism、MPTP-induced experimental parkinsonism、parkinsonian disorder、parkinsonian syndrome、parkinsonism
[★]
常染色体劣性若年性パーキンソン病、常染色体劣性若年性Parkinson病
- 関
- autosomal dominant parkinsonism、autosomal recessive juvenile parkinsonism、autosomal recessive parkinsonism、experimental parkinsonism、juvenile Parkinson disease、juvenile parkinsonism、MPTP-induced experimental parkinsonism、parkinsonian disorder、parkinsonian syndrome、parkinsonism
[★]
若年性パーキンソン病、若年性Parkinson病
- 関
- autosomal dominant parkinsonism、autosomal recessive juvenile Parkinson disease、autosomal recessive juvenile parkinsonism、autosomal recessive parkinsonism、experimental parkinsonism、juvenile parkinsonism、MPTP-induced experimental parkinsonism、parkinsonian disorder、parkinsonian syndrome、parkinsonism
[★]
- 関
- parkinsonian-like、parkinsonism
[★]